secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2022-06-07T23:59:59+00:00
Accession:  0001140361-22-022218
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Brooklyn ImmunoTherapeutics replaces four directors; appoints Angel, Fiore, Wexler, Singer
--------------------------------------------------------------------------------

- Four directors (Langer, Mohr, Enright, Redman) resigned effective June 5, 2022; no disagreement cited.
- Board size reduced from six to five; then appointed four new directors to fill vacancies.
- Appointees include Matthew Angel (interim CEO), Gregory Fiore (CEO of Exacis), William Wexler (restructuring expert), Nicholas Singer (founder of Purchase Capital).
- Wexler and Singer deemed independent; Singer qualifies as audit committee financial expert.
- No material transactions with new directors except prior rights offering participation by Singer ($1.29M) and Angel's prior appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/0001140361-22-022218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/brhc10038551_form8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-022218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer